Sarcoma Study Details

Reference

ASSG21-EEO8

 Short title

The study is open to patients with Ewing sarcomas, localised or metastatic, who are considered eligible for neoadjuvant chemotherapy. All patients will receive induction chemotherapy consisting of six cycles of vincristine, ifosfamide, doxorubicin and etoposide (VIDE). The decision regarding local therapy must be made following the fifth cycle of induction treatment, with a preference for surgical intervention with or without additional radiotherapy. Patients are categorised into three risk groups; within each risk group, the patient is then randomised to one of two study arms for further chemotherapy. 


Australian Sites

Monash Medical Centre, Peter MacCallum Cancer Centre, Royal Children's - Melbourne, Princess Margaret Hospital for Children, Starship, Christchurch Hospital (children), Chris O'Brien Lifehouse, Westmead Hospital, Lady Cilento (Brisbane)


 Open
2014
Contacts

Dr Vivek Bhadri (vivek.bhadri@lh.org.au)


 Go back to Sarcoma Studies
 Find a Sarcoma Specialist
 Ask a Question
Support Sarcoma Research